Mark R. Middleton

30.3k citations

372 papers · 13.6k indexed · 4 hit papers · h-index 63

Impact in

Oncology top 0.1%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
Immunology top 1%
- Immunotherapy and Immune Responses

Papers in

Oncology 212
- CAR-T cell therapy research 71
- Cancer Immunotherapy and Biomarkers 64
- Cutaneous Melanoma Detection and Management 41
- Colorectal Cancer Treatments and Studies 24
Immunology 73
- Immunotherapy and Immune Responses 49

Co-authors: Jean‐Jacques Grob Fergus Gleeson Feng Wu Gail ter Haar David Cranston Geoffrey P. Margison Rachel R. Phillips Josep Malvehy
Journals: Journal of Clinical Oncology (78 papers)Annals of Oncology (33 papers)British Journal of Cancer (25 papers)Clinical Cancer Research (17 papers)European Journal of Cancer (16 papers)
Partner nations: United Kingdom United States Australia

In The Last Decade

Mark R. Middleton

359 papers receiving 13.3k citations

Hit Papers

align trajectories log scale

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study 2018 · 302 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2015 European Journal of Cancer
2015 European Journal of Cancer
2000 Journal of Clinical Oncology

Peers

Countries citing papers authored by Mark R. Middleton

Since Specialization

Citations

This map shows the geographic impact of Mark R. Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Middleton more than expected).

Fields of papers citing papers by Mark R. Middleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Middleton. The network helps show where Mark R. Middleton may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark R. Middleton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark R. Middleton Line = papers co-authored together Mark R. Middleton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma Annals of Oncology ·Paolo A. Ascierto, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, L. L., Jacopo Pigozzo, Iván Márquez‐Rodas, Wang Mengwu, Anna Maria Di Giacomo, Mark R. Middleton, 余向丽, Luis de la Cruz‐Merino, Chizmadzhev YuA, Consello Galego de Relacións Laborais, Margarita Askelson, James Larkin	2025	0
2	750P Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC) Annals of Oncology ·Claire F. Friedman, Wang Junzuo, Juanita Lopez, Pitkäpaasi M, Mark R. Middleton, Fiona Thistlethwaite, Omid Hamid, Benjamin Izar, Adilaimu Tiliman, M.L. Johnson, Ary Mailhos, Juan Martín-Liberal, Nick Homburg, N S Dobina, Daniel G. Olson, 奈都美松浦, T. de O. Barroso, Lulu Que, Shannon Marshall, Yongsheng Cai	2024	1
3	Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048. Journal of Clinical Oncology ·Paolo A. Ascierto, Reinhard Dummer, Caroline Gaudy‐Marqueste, Samantha Bowyer, Evan J. Lipson, Eleonora Ghisoni, Mark R. Middleton, MM. Lucas, 陈国庭, 忠司田畑, M. A. Raifeld, Priya Kannan, Georgina V. Long	2024	15
4	Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells iScience ·Ashwin Jainarayanan, صدیقه طوافیان, Edward H. Arbe-Barnes, 雅枝長谷川, Rachael Bashford-Rogers, Adam E. Frampton, Lara R. Heij, Mark R. Middleton, Michael L. Dustin, Enas Abu‐Shah, Shivan Sivakumar	2023	5
5	Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment PubMed ·Luiz Heleno Ribeiro Delgado, Mark R. Middleton	2023	25
6	VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface Clinical Cancer Research ·Vinton W.T. Cheng, Nick de Pennington, Rasheed Zakaria, James R. Larkin, Sébastien Serres, S. Sudha Mercy, Matthew A. Kirkman, Claire Bristow, Paula Croal, Puneet Plaha, Leticia Campo, Michael A. Chappell, Simon Lord, Michael D. Jenkinson, Mark R. Middleton, Nicola R. Sibson	2022	16
7	Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles British Journal of Cancer ·Weiyu Ye, Anna Olsson‐Brown, Robert Watson, Vincent Cheung, Robert D. Morgan, Isar Nassiri, Rosalin Cooper, Chelsea Taylor, Thierry Lauthelier, Oliver Brain, Rubeta Matin, Nicholas Coupe, Mark R. Middleton, Mark Coles, Joseph J. Sacco, Miranda Payne, Benjamin P. Fairfax	2021	33
8	sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients Clinical Cancer Research ·Mitchell E. Fane, Brett L. Ecker, Amanpreet Kaur, Gloria E. Marino, Gretchen M. Alicea, Stephen M. Douglass, Yash Chhabra, Marie R. Webster, Andrea Marshall, Richard Colling, T.F.T., Nicholas Coupe, Hisato Hara, Leticia Campo, Mark R. Middleton, Pippa Corrie, Xiaowei Xu, Giorgos C. Karakousis, Ashani T. Weeraratna	2020	22
9	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma Clinical Cancer Research ·Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock, Pippa Corrie, Jeffrey R. Infante, Neil Steven, T.R. Jeffry Evans, Alan Anthoney, Alexander N. Shoushtari, Omid Hamid, Avinash Gupta, Antonella Vardeu, Emma Leach, Revashnee Naidoo, سید محمد مهدی احمدی اصفهانی, Sion Lewis, Jacob Hurst, Anne M. Kelly, Mario Sznol	2020	165
10	Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma Nature Medicine ·Benjamin P. Fairfax, Chelsea Taylor, Robert Watson, Isar Nassiri, Sara Danielli, Hai Fang, Elise A. Mahé, Rosalin Cooper, Victoria K. Woodcock, Zoë Traill, Hussein Al‐Mossawi, Julian C. Knight, Paul Klenerman, Miranda Payne, Mark R. Middleton	2020	198
11	Bony increased-offset reverse shoulder arthroplasty: A meta-analysis of the available evidence Shoulder & Elbow ·Y. Yang, Rayhona Sa'dullayeva, Mohamed A. Imam, Mark R. Middleton, Arnaud Godenèche, A Narvani	2020	19
12	VCAM-1–targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors Clinical Cancer Research ·Vinton W.T. Cheng, Manuel Sarmiento Soto, Alexandre A. Khrapitchev, Francisco Pérez-Balderas, Rasheed Zakaria, Michael D. Jenkinson, Mark R. Middleton, Nicola R. Sibson	2018	28
13	Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Journal of Clinical Oncology ·Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Jankú, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiss‐Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga Hit paper breakdown →	2018	302
14	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy Nature Communications ·John M. Findlay, Francesc Castro-Giner, Seiko Makino, Emily Rayner, Christiana Kartsonaki, William Cross, Michal Kováč, William Wyman, Claire Palles, Richard Gillies, Eder Antônio Costa de Araújo, David N. Church, Nicholas Maynard, Francesca M. Buffa, Jean‐Baptiste Cazier, Trevor A. Graham, P. Jose, Ricky A. Sharma, Mark R. Middleton, Ian Tomlinson	2016	65
15	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations Clinical Cancer Research ·Lisa Zimmer, Fabrice Barlési, Maria Martinez‐García, Véronique Dièras, Jan H.M. Schellens, Jean‐Philippe Spano, Mark R. Middleton, Emiliano Calvo, L. Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber‐Bodéré, Jean Tessier, Wilfried Eberhardt, Michel Pâques, Ernesto Guarin, Valérie Méresse, Jean‐Charles Soria	2014	59
16	Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors Clinical Cancer Research ·Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber‐Bodéré, Véronique Dièras, M. E. Scheulen, Avinash Gupta, Vanesa López-Valverde, Zhixin Xu, Ruediger Rueger, Jean Tessier, Eliezer Shochat, Fan Weiyan, Xiaofei Gao, Jan H.M. Schellens, Wilfried Eberhardt	2012	55
17	Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma Clinical Cancer Research ·John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark R. Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, Reinhard Dummer	2011	218
18	Using risk matrices Mark R. Middleton, Anne Heldenbergh	2001	12
19	O6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts International Journal of Cancer ·Mark R. Middleton, Jane Kelly, Nicholas Thatcher, Dorothy J. Donnelly, R. Stanley McElhinney, T. Brian H. McMurry, Joan E. McCormick, Geoffrey P. Margison	2000	44
20	O6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts International Journal of Cancer ·Mark R. Middleton, Jane Kelly, Nicholas Thatcher, Dorothy J. Donnelly, R. Stanley McElhinney, T. Brian H. McMurry, Joan E. McCormick, Geoffrey P. Margison	2000	69

About Mark R. Middleton

Mark R. Middleton is a scholar working on Oncology, Immunology, Cancer Research, Genetics and Molecular Biology, having authored 372 papers that have together received 13.6k indexed citations. Recurring topics across this work include CAR-T cell therapy research (71 papers), Cancer Immunotherapy and Biomarkers (64 papers), Melanoma and MAPK Pathways (63 papers), Immunotherapy and Immune Responses (49 papers), Cutaneous Melanoma Detection and Management (41 papers), Colorectal Cancer Treatments and Studies (24 papers), Esophageal Cancer Research and Treatment (24 papers) and Cancer therapeutics and mechanisms (22 papers). The work is most often cited by research in Oncology (7.3k citations), Immunology (2.3k citations), Molecular Biology (6.2k citations), Cancer Research (1.3k citations) and Genetics (864 citations). Mark R. Middleton has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Jean‐Jacques Grob, Fergus Gleeson, Feng Wu, Gail ter Haar, David Cranston, Geoffrey P. Margison, Rachel R. Phillips, Josep Malvehy, Ketty Peris and Hubert Pehamberger. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Clinical Cancer Research and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact